# Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06903377/  
OnCo record `nct06903377` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gecacitinib in non-small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06903377 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 50 participants planned, started 2025-05-23 and due to reach its primary completion in 2027-04. Interventions recorded: ZG005 for Injection and Gecacitinib Hydrochloride Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06903377
- Phase: 1/2
- Setting: A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06903377: https://clinicaltrials.gov/study/NCT06903377

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Gecacitinib](https://onco.cc/drugs/gecacitinib/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06903377.json